A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon) on Glucose Control in Patients With Type I Diabetes

Next Previous
Trial Profile

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon) on Glucose Control in Patients With Type I Diabetes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018.
    • 05 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top